Difference between revisions of "Cisplatin (Platinol)"
Jump to navigation
Jump to search
m |
m |
||
| Line 11: | Line 11: | ||
*[[Anal cancer]] | *[[Anal cancer]] | ||
*[[Anaplastic large cell lymphoma]] | *[[Anaplastic large cell lymphoma]] | ||
| − | |||
| − | |||
*[[Bladder cancer]] | *[[Bladder cancer]] | ||
*[[Breast cancer]] | *[[Breast cancer]] | ||
| + | *[[Carcinoma of unknown primary]] | ||
*[[Cervical cancer]] | *[[Cervical cancer]] | ||
*[[Cholangiocarcinoma]] | *[[Cholangiocarcinoma]] | ||
| + | *[[Cutaneous basal cell carcinoma]] | ||
| + | *[[Cutaneous squamous cell carcinoma]] | ||
*[[Diffuse large B-cell lymphoma]] | *[[Diffuse large B-cell lymphoma]] | ||
*[[Endometrial cancer]] | *[[Endometrial cancer]] | ||
*[[Esophageal cancer]] | *[[Esophageal cancer]] | ||
| + | **[[Esophageal adenocarcinoma]] | ||
*[[Extranodal NK- and T-cell lymphoma, nasal type]] | *[[Extranodal NK- and T-cell lymphoma, nasal type]] | ||
*[[Gastric cancer]] | *[[Gastric cancer]] | ||
| Line 39: | Line 41: | ||
*[[Primary mediastinal B-cell lymphoma]] | *[[Primary mediastinal B-cell lymphoma]] | ||
*[[Small cell lung cancer]] | *[[Small cell lung cancer]] | ||
| − | |||
*[[Testicular cancer]] | *[[Testicular cancer]] | ||
*[[Thymoma]] | *[[Thymoma]] | ||
| Line 167: | Line 168: | ||
[[Category:Diffuse large B-cell lymphoma medications]] | [[Category:Diffuse large B-cell lymphoma medications]] | ||
[[Category:Endometrial cancer medications]] | [[Category:Endometrial cancer medications]] | ||
| + | [[Category:Esophageal adenocarcinoma medications]] | ||
[[Category:Esophageal cancer medications]] | [[Category:Esophageal cancer medications]] | ||
[[Category:Extranodal NK- and T-cell lymphoma, nasal type medications]] | [[Category:Extranodal NK- and T-cell lymphoma, nasal type medications]] | ||
Revision as of 01:41, 1 May 2022
General information
Class/mechanism: Platinum analog, alkylating-like, producing predominantly interstrand DNA crosslinks that are cell-cycle nonspecific.[1][2]
Route: IV, intracavitary (intraperitoneal)
Extravasation: vesicant (concentration ≥0.5 mg/mL)/irritant (concentration <0.5 mg/mL)
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Adrenocortical carcinoma
- Anal cancer
- Anaplastic large cell lymphoma
- Bladder cancer
- Breast cancer
- Carcinoma of unknown primary
- Cervical cancer
- Cholangiocarcinoma
- Cutaneous basal cell carcinoma
- Cutaneous squamous cell carcinoma
- Diffuse large B-cell lymphoma
- Endometrial cancer
- Esophageal cancer
- Extranodal NK- and T-cell lymphoma, nasal type
- Gastric cancer
- Head and neck cancer
- Hepatoblastoma
- Hodgkin lymphoma
- Low-grade glioma
- Mantle cell lymphoma
- Melanoma
- Mesothelioma
- Multiple myeloma
- Nasopharyngeal carcinoma
- Non-small cell lung cancer
- Osteosarcoma
- Ovarian cancer
- Pancreatic cancer
- Penile cancer
- Peripheral T-cell lymphoma
- Primary mediastinal B-cell lymphoma
- Small cell lung cancer
- Testicular cancer
- Thymoma
- Transformed lymphoma
- Upper tract urothelial carcinoma
- Vulvar cancer
Patient drug information
- Cisplatin (Platinol) package insert[1]
- Cisplatin (Platinol) patient drug information (Chemocare)[3]
- Cisplatin (Platinol) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 12/19/1978: Initial FDA approval
- 9/2/2010: (earliest label available at Drugs@FDA) Indicated in established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures.
- 9/2/2010: (earliest label available at Drugs@FDA) Indicated in established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of PLATINOL and cyclophosphamide. PLATINOL, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received PLATINOL therapy.
- 9/2/2010: (earliest label available at Drugs@FDA) Indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy.
Also known as
- Code name: NSC 119875
- Generic names: CDDP, cis-diamminedichloroplatinum III, cis-platinum, cisplatinum, DACP, DDP
- Brand names:
| Synonyms | |||||||
|---|---|---|---|---|---|---|---|
| Abiplatin | Axiplat | Biocisplatinum | Bioplatino | Blastolem | Briplatin | Brisplatin | C-Platin |
| Ceplatin | Ciplatan | Ciplexal | Cis-GRY | Cismaplat | Cispatin | Cisplamerck | Cisplan |
| Cisplasol | Cisplatex | Cisplatine | Cisplatino | Cisplatyl | Cisteen | Citoplatino | Citosin |
| Cysplatyna | Cytoplatin | Docistin | Elvecis | Fauldcispla | Ifapla | Kemoplat | Lederplatin |
| Metaplatin | Neoplat | Neoplatin | Noveldexis | Oncoplatin AQ | Peyrone's Chloride | Peyrone's Salt | Placis |
| Plastistil | Platamin | Platamine | Platiblastin | Platicis | Platidiam | Platikem | Platil |
| Platimit | Platin | Platinex | Platinil | Platino II Filaxis | Platinol | Platinox | Platinoxan |
| Platiran | Platistil | Platistin | Platistine | Platosin | Randa | Romcis | Sicatem |
| Sinplatin | Sisplanil | Tecnoplatin | Tisplal | Unistin | |||
References
Categories:
- Drugs
- Intravenous medications
- Intracavitary medications
- Vesicant
- Irritant
- Platinum agents
- Alkylating agents
- Carcinoma of unknown primary medications
- Adrenocortical carcinoma medications
- Anal cancer medications
- Anaplastic large cell lymphoma medications
- Cutaneous basal cell carcinoma medications
- Bladder cancer medications
- Breast cancer medications
- Cervical cancer medications
- Cholangiocarcinoma medications
- Diffuse large B-cell lymphoma medications
- Endometrial cancer medications
- Esophageal adenocarcinoma medications
- Esophageal cancer medications
- Extranodal NK- and T-cell lymphoma, nasal type medications
- Gastric cancer medications
- Head and neck cancer medications
- Hepatoblastoma medications
- Hodgkin lymphoma medications
- Low-grade glioma medications
- Mantle cell lymphoma medications
- Melanoma medications
- Mesothelioma medications
- Multiple myeloma medications
- Nasopharyngeal carcinoma medications
- Non-small cell lung cancer medications
- Osteosarcoma medications
- Ovarian cancer medications
- Pancreatic cancer medications
- Penile cancer medications
- Peripheral T-cell lymphoma medications
- Primary mediastinal B-cell lymphoma medications
- Small cell lung cancer medications
- Cutaneous squamous cell carcinoma medications
- Testicular cancer medications
- Thymoma medications
- Transformed lymphoma medications
- Upper tract urothelial carcinoma medications
- Vulvar cancer medications
- FDA approved in 1978
- WHO Essential Cancer Medicine